Zhifei Lin
Impact in
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- RNA modifications and cancer 3
-
- Cancer, Hypoxia, and Metabolism 4
- MicroRNA in disease regulation 2
- Co-authors
- Jinhong Chen (11 shared papers)Lun–Xiu Qin (8 shared papers)Hu‐Liang Jia (8 shared papers)Jubo Zhang (7 shared papers)Lu Lu (9 shared papers)Ming Lü (6 shared papers)Wenwei Zhu (7 shared papers)Weiqing Shao (7 shared papers)
- Journals
- Clinical and Experimental Dermatology (2 papers)Journal of Hematology & Oncology (2 papers)Cell Metabolism (1 paper)Neoplasia (1 paper)Theoretical and Applied Genetics (1 paper)
- Partner nations
- China
In The Last Decade
Zhifei Lin
20 papers receiving 1.3k citations
Zhifei Lin's Hit Papers
Peers
Comparison fields: 5 of 85
- Cancer Research 405
- Hepatology 159
- Immunology 413
- Oncology 313
- Molecular Biology 660
Countries citing papers authored by Zhifei Lin
This map shows the geographic impact of Zhifei Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhifei Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhifei Lin more than expected).
Fields of papers citing papers by Zhifei Lin
This network shows the impact of papers produced by Zhifei Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhifei Lin. The network helps show where Zhifei Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Zhifei Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 271 | |
| 2 | Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC Hit paper breakdown → | 2021 | 212 |
| 3 | 2021 | 128 | |
| 4 | 2019 | 118 | |
| 5 | 2012 | 112 | |
| 6 | 2021 | 107 | |
| 7 | 2019 | 101 | |
| 8 | 2020 | 60 | |
| 9 | 2022 | 52 | |
| 10 | 2015 | 24 | |
| 11 | 2022 | 23 | |
| 12 | 2019 | 22 | |
| 13 | 2022 | 18 | |
| 14 | 2009 | 14 | |
| 15 | 2023 | 10 | |
| 16 | 2018 | 9 | |
| 17 | 2022 | 7 | |
| 18 | 2022 | 3 | |
| 19 | 2016 | 2 | |
| 20 | 2017 | 1 |
About Zhifei Lin
Zhifei Lin is a scholar working on Molecular Biology, Cancer Research, Surgery, Oncology and Cell Biology, having authored 22 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (4 papers), Skin and Cellular Biology Research (3 papers), RNA modifications and cancer (3 papers), Immune cells in cancer (3 papers), Autophagy in Disease and Therapy (3 papers), MicroRNA in disease regulation (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Nanoplatforms for cancer theranostics (2 papers). The work is most often cited by research in Cancer Research (405 citations), Hepatology (159 citations), Immunology (413 citations), Oncology (313 citations) and Molecular Biology (660 citations). Zhifei Lin has collaborated with scholars based in China. Frequent co-authors include Jinhong Chen, Lun–Xiu Qin, Hu‐Liang Jia, Jubo Zhang, Lu Lu, Ming Lü, Wenwei Zhu, Weiqing Shao, Wenwei Zhu and B. Liu. Their work appears in journals such as Clinical and Experimental Dermatology, Journal of Hematology & Oncology, Cell Metabolism, Neoplasia and Theoretical and Applied Genetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.